Close Menu

Oxford Nanopore

Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Oxford Nanopore's instruments — MinIon, PromethIon, and GridIon are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule.

Oxford Nanopore Facts


CEO: Gordon Sanghera


Ticker symbol: Privately held

Headquarters: Oxford, UK

Number of employees: 250+

By Julia Karow
The National Human Genome Research Institute has awarded about $14.5 million in grants to nine research groups developing new DNA sequencing technologies to sequence a human genome for $1,000 or less.

A pan-European consortium plans to develop infrastructure to create virtual models that will help physicians tailor treatments to individual genetic and physiological characteristics.

The company is also expanding its staff, with 18 current openings, including one for vice president of manufacturing and operations.

Oxford Nanopore is expanding its headquarters and opening a new bioinformatics outstation in Cambridge, UK, and plans to hire around a dozen bioinformaticians and computational scientists.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Beckman Coulter announced changes to its board, Steven Salzberg moves to Johns Hopkins, Complete Genomics names a new senior vice president and chief commercial officer, and more.

Paired Ends: Jun 28, 2011


Peter Allen, Riccardo Pigliucci, Keith Raffel, Mark Sutherland, Steven Salzberg, Mihai Pop

The NIH's plans for trimming grants this year topped the list of most-read articles last week.

The funding will allow the company to validate its technology, including "interacting with key users who represent the spectrum of the particular application area, whether it's protein analysis or sequencing, and then ultimately, through commercialization," said CEO Gordon Sanghera.

The UK firm will use the funding to support further development, external validation, and production capabilities for its technology in DNA sequencing and protein analysis applications.


The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.